UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
10.87
-0.17 (-1.54%)
Dec 27, 2024, 10:04 AM EST - Market open
UroGen Pharma Employees
As of December 31, 2023, UroGen Pharma had 201 total employees, including 198 full-time and 3 part-time employees. The number of employees increased by 1 or 0.50% compared to the previous year.
Employees
201
Change (1Y)
1
Growth (1Y)
0.50%
Revenue / Employee
$444,592
Profits / Employee
-$574,020
Market Cap
458.71M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Emergent BioSolutions | 1,600 |
| Esperion Therapeutics | 240 |
| Allogene Therapeutics | 233 |
| Alpha Teknova | 211 |
| Arcturus Therapeutics Holdings | 180 |
| Alumis | 109 |
| PureTech Health | 90 |
| Zevra Therapeutics | 69 |
URGN News
- 21 days ago - UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 21 days ago - Long-Term Follow-up Study to the OLYMPUS Trial Presented at SUO 2024 Reports Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO® - Business Wire
- 21 days ago - UGN-102 Showed Promising Long-Term Results in the Phase 3 ENVISION Trial, Potentially Paving the Way for First FDA-Approved Treatment for LG-IR-NMIBC - Business Wire
- 25 days ago - UroGen Announces New Data Presentations at the Society of Urologic Oncology 2024 Annual Meeting Highlighting Urothelial Cancer Portfolio Aimed at Addressing Unmet Needs - Business Wire
- 4 weeks ago - New Data from a Long-Term Follow-up Study to the OLYMPUS Trial Show Median Duration of Response of Four Years in Patients Who Achieved a Complete Response with JELMYTO® - Business Wire
- 5 weeks ago - Undercovered Dozen: Aurora Cannabis, FREYR Battery, Royalty Pharma, Talos Energy + - Seeking Alpha
- 6 weeks ago - UroGen Pharma: Choice Based On Near Term High Value PDUFA - Seeking Alpha
- 7 weeks ago - UroGen Pharma Ltd. (URGN) Q3 2024 Earnings Call Transcript - Seeking Alpha